Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-176 in Healthy Adults

NCT04471038 is registered in ClinicalTrials.gov with SAb Biotherapeutics, Inc. as lead sponsor.

NCT NCT04471038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-176 in Healthy Adults
Lead sponsor
SAb Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 29, 2020
Completion date
April 19, 2021
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, influenza type a, influenza type b